Table 23
|  | IA before HCT No (N = 1432) | IA before HCT Yes (N = 95) | Total (N = 1527) |
|---|---|---|---|
Age at HCT Median (min – max) | 40.9 (0.4–75.8) | 36.6 (1.2–68.0) | 40.9 (0.4–75.8) |
Interval from IA to HCT (months) |  | 6.6 (2.2–165.3) |  |
Underlying malignancy | Â | Â | Â |
 ALL | 460 (32.1) | 33 (34.7) | 493 (32.3) |
 AML | 972 (67.9) | 62 (65.3) | 1034 (67.7) |
Acute leukemia status before HCT | Â | Â | Â |
 Other | 1099 (76.7) | 79 (83.2) | 1178 (77.1) |
 CR | 310 (21.6) | 15 (15.8) | 325 (21.3) |
Donor type | Â | Â | Â |
 HLA-identical sibling | 363 (25.3) | 38 (40.0) | 401 (26.3) |
 Haploidentical | 233 (16.3) | 17 (17.9) | 250 (16.4) |
 Unrelated donor | 836 (58.4) | 40 (42.1) | 876 (57.4) |
Stem cell source | Â | Â | Â |
 Bone marrow | 373 (26.0) | 20 (21.1) | 393 (25.7) |
 Peripheral Blood | 1014 (70.8) | 72 (75.8) | 1086 (71.1) |
 Cord Blood | 45 (3.1) | 3 (3.2) | 48 (3.1) |
Conditioning regimen | Â | Â | Â |
 Myeloablative | 1081 (75.5) | 80 (84.2) | 1161 (76.0) |
 Reduced | 348 (24.3) | 14 (14.7) | 362 (23.7) |
Total body irradiation | Â | Â | Â |
 No | 999 (69.8) | 62 (65.3) | 1061 (69.5) |
 Yes | 430 (30.0) | 30 (31.6) | 460 (30.1) |
In-vivo T-cell depletion | Â | Â | Â |
 No | 714 (49.9) | 51 (53.7) | 765 (50.1) |
 Yes | 716 (50.0) | 43 (45.3) | 759 (49.7) |
